Featured Research

from universities, journals, and other organizations

Antiretroviral Therapy As HIV Prevention Strategy

Date:
July 1, 2008
Source:
Canadian Medical Association Journal
Summary:
The widespread use of highly active antiretroviral therapy may reduce the incidence of HIV in individuals and populations but has been overlooked by public health as a prevention strategy.

The widespread use of highly active antiretroviral therapy may reduce the incidence of HIV in individuals and populations but has been overlooked by public health as a prevention strategy, write Dr. Julio Montaner and colleagues in CMAJ.

Despite advances in HIV treatment such as topical microbicides, pre- and post-exposure treatment and male circumcision, HIV infections continue to increase worldwide. Dr. Montaner and co-authors argue that "expanded access to highly active antiretroviral therapy for patients with a medical indication will reduce AIDS-related illness and deaths and may reduce HIV incidence."

"At the population level, access to highly active antiretroviral therapy has been temporally associated with substantial reductions in HIV incidence. For example, population-based research in Taiwan found a 53% reduction in new positive HIV test results after the introduction of free access to highly active antiretroviral therapy."

The use of "treatment as an aid to prevention" has been used in public health disease management, with diseases such as tuberculosis and genital herpes. "However, public health policy-makers and program managers have been reluctant to accept this strategy as viable for preventing the growth of the HIV/AIDS epidemic," write the authors.

"Treatment as an aid to prevention should be explored in diverse settings, including in developed and developing countries....Evidence derived from these research efforts will decrease AIDS-related morbidity and mortality and inform policy-makers about the role of treatment as an aid to prevention."


Story Source:

The above story is based on materials provided by Canadian Medical Association Journal. Note: Materials may be edited for content and length.


Cite This Page:

Canadian Medical Association Journal. "Antiretroviral Therapy As HIV Prevention Strategy." ScienceDaily. ScienceDaily, 1 July 2008. <www.sciencedaily.com/releases/2008/06/080630165435.htm>.
Canadian Medical Association Journal. (2008, July 1). Antiretroviral Therapy As HIV Prevention Strategy. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/06/080630165435.htm
Canadian Medical Association Journal. "Antiretroviral Therapy As HIV Prevention Strategy." ScienceDaily. www.sciencedaily.com/releases/2008/06/080630165435.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins